The impact of dietary calcium intake and vitamin D status on the effects of zoledronate

• Published in: Osteoporosis international 2013-01, Vol.24 (1), p.349-354
• Main Authors: Bourke, S., Bolland, M. J., Grey, A., Horne, A. M., Wattie, D. J., Wong, S., Gamble, G. D., Reid, I. R
• Format: Article
• Language: English
• Subjects: Acute-Phase Reaction - chemically induced; Aged; Bone density; Bone Density - drug effects; Bone Density Conservation Agents - administration & dosage; Bone Density Conservation Agents - adverse effects; Bone Density Conservation Agents - pharmacology; Bone Remodeling - drug effects; Calcium; Calcium, Dietary - administration & dosage; Calcium, Dietary - pharmacology; Dietary supplements; Diphosphonates - administration & dosage; Diphosphonates - adverse effects; Diphosphonates - pharmacology; Dose-Response Relationship, Drug; Drug therapy; Endocrinology; Female; Food-Drug Interactions - physiology; Hip Joint - physiopathology; Humans; Imidazoles - administration & dosage; Imidazoles - adverse effects; Imidazoles - pharmacology; Lumbar Vertebrae - physiopathology; Medicine; Medicine & Public Health; Middle Aged; Original Article; Orthopedics; Osteoporosis, Postmenopausal - blood; Osteoporosis, Postmenopausal - drug therapy; Osteoporosis, Postmenopausal - physiopathology; Randomized Controlled Trials as Topic; Rheumatology; Vitamin D; Vitamin D - analogs & derivatives; Vitamin D - blood
• ISSN: 0937-941X; 1433-2965
• DOI: 10.1007/s00198-012-2117-4

Summary We investigated whether baseline dietary calcium intake or vitamin D status modified the effects of zoledronate. Neither variable influenced the effect of zoledronate on bone mineral density, bone turnover, or risk of acute phase reaction, suggesting that co-administration of calcium and vitamin D supplements with zoledronate may not always be necessary. Introduction Calcium and vitamin D supplements are often co-administered with bisphosphonates, but it is unclear whether they are necessary for therapeutic efficacy or minimizing side effects of bisphosphonates. We investigated whether baseline dietary calcium intake or vitamin D status modified the effect of zoledronate on bone mineral density (BMD) or bone turnover at 1 year, or the risk of acute phase reactions (APR). Methods Data were pooled from two trials of zoledronate in postmenopausal women without vitamin D deficiency in which calcium and vitamin D were not routinely administered. The cohort (zoledronate n  = 154, placebo n  = 68) was divided into subgroups by baseline dietary calcium intake (